Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75 years

Taner, C. Burcin; Ung, Ryan; Rosser, Barry G.; Aranda-Michel, Jaime

doi:10.1007/s12072-011-9286-7

Cited by 31 publications

(28 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elderly patients had more often renal failure after LDLT than younger patients. Taner et al 22 evaluated the results of recipients older than 75 years, who underwent liver transplantation from deceased donor. This retrospective review of 13 patients came to the result that age alone is not an absolute contraindication and that also individuals older than 75 years can undergo a liver transplantation with acceptable long-term survival.…”

Section: Discussionmentioning

confidence: 99%

“…The life expectancy of a healthy 70-year-old person is, in the literature, reported to be 10 to 12 years. 22 It is likely that the life expectancy of a patient 70 years or older with end stage liver disease, even with a low MELD score is shorter than 10 years. All of our patients had at least one complication of their liver cirrhosis, such as hepatic encephalopathy, variceal bleeding, or spontaneous bacterial peritonitis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Living Donor Liver Transplantation in Patients 70 Years or Older

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Living Donor Liver Transplantation in Patients 70 Years or Older

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In the study by Taner et al [57] , 13 transplanted patients ≥ 75 years experienced a favorable outcome and seven of them experienced a mean survival of 65 mo. A large-scale survey from Switzerland concluded that advanced age was not a significant predictor of survival [58] .…”

Section: Liver Transplantationmentioning

confidence: 98%

“…Data on survival and disease free survival in old and young patients undergoing HCC resection are reported in Table 1. Post-operative mortality in elderly patients was reported to range from 0 to 3.2% [25,[34][35][36][37][38][39][40][41][42][48][49][50][55][56][57] . In two retrospective studies from Far East, surgeryrelated in-hospital morbidity and mortality were not significantly different in older as compared to younger patient [26,50] .…”

Section: Resectionmentioning

confidence: 99%

Management of hepatocellular carcinoma in the elderly

Borzio

Dionigi

Parisi

et al. 2015

WJH

View full text Add to dashboard Cite

recommendation. We carried out a literature search in MEDLINE database for studies reporting on epidemiology, clinical characteristics and treatment outcome of HCC in elderly patients. Available data seem to indicate that in elderly patients the outcome of HCC is mostly influenced by liver function and tumor stage rather than by age and the latter should not influence treatment allocation. Age is not a risk for resection and older patients with resectable HCC and good liver function could gain benefit from surgery. Mild comorbidities do not seem a contraindication for surgery in aged patients. Conversely, major resection in elderly, even when performed in experienced high-volume centres, should be avoided. Both percutaneous ablation and transarterial chemoembolization are not contraindicated in aged patients and safety profile of these procedures is acceptable. Sorafenib is a viable option for advanced HCC in elderly provided that a careful evaluation of concomitant comorbidities, particularly cardiovascular ones, is taken into account. Available data seem to suggest that in either elderly and younger, treatment is a main predictor of outcome. Consequently, a nihilistic attitude of physicians towards under-or no-treatment of aged patients should not be longer justified. Core tip: The number of elderly patients with cancer is expected to rise in the next future, and facing with elderly cirrhotic patients with hepatocellular carcinoma (HCC) will characterize liver oncology scenario in the near future. International guidelines do not specifically address how to approach HCC in aged patients and no recommendations are available on age threshold to which clinical decisions should refer. Available data seem to rule out an intrinsic negative impact of age itself on HCC prognosis, and treatment allocation should be decided mainly according to HCC stage, liver residual function and general conditions. Indeed, a nihilistic AbstractMean age of hepatocellular carcinoma (HCC) patients has been progressively increasing over the last decades and ageing of these patients is becoming a real challenge in every day clinical practice. Unfortunately, international guidelines on HCC management do not address this problem exhaustively and do not provide any specific REVIEWSubmit a

show abstract

“…There is an arbitrary age limit for LT because of the increased comorbidity in elderly patients 68. In general, HCC patients aged >65-70 years are not considered as potential candidates for LT 69.…”

Section: Ltmentioning

confidence: 99%

Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review

Nishikawa¹,

Kimura²,

Kita³

et al. 2013

J. Cancer

View full text Add to dashboard Cite

An aging society means that the number of elderly patients with cancer is predicted to rise in the future. Hepatocellular carcinoma (HCC) usually develops in patients with hepatitis B virus infection, hepatitis C virus infection, or alcoholic liver disease. The risk of developing HCC is also known to be age-dependent and elderly patients sometimes present with HCC. The increased longevity of the population thus means that more elderly HCC patients are to be expected in the coming years. In general, many elderly patients are not receiving optimal therapy for malignancies, because it is often withheld from them because of perceived minimal survival advantage and the fear of potential toxicity. Comprehensive data with regard to treatment of elderly patients with HCC are currently limited. Furthermore, current guidelines for the management of HCC do not satisfy strategies according to age. Thus, there is urgent need for investigation of safety and clinical outcomes in elderly patients who receive therapy for HCC. In this review, we primarily refer to current knowledge of clinical characteristics and outcome in elderly patients with HCC who underwent different treatment approaches (i.e., surgical resection, liver transplantation, locoregional therapies, and molecular-targeting therapy).

show abstract

Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75 years

Abstract: Our study demonstrates that a with proper evaluation and careful consideration of risk factors, individuals older than 75 years of age can undergo this life-saving procedure with acceptable long-term survival.

Cited by 31 publications

References 16 publications

Living Donor Liver Transplantation in Patients 70 Years or Older

Living Donor Liver Transplantation in Patients 70 Years or Older

Management of hepatocellular carcinoma in the elderly

Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review

Contact Info

Product

Resources

About